(Q34618814)

3 August 2017

1 reference

title

Current and emerging treatment options in chronic myeloid leukemia (English)

1 reference

3 August 2017

chronic myeloid leukemia

0 references

1 reference

5

Hagop M Kantarjian

1 reference

3 August 2017

4

Susan O'Brien

1 reference

3 August 2017

1

Elias Jabbour

1 reference

3 August 2017

2

Jorge E Cortes

1 reference

3 August 2017

3

Francis J Giles

1 reference

PubMed ID

17431887

3 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

3 August 2017

1 reference

3 August 2017

109

1 reference

3 August 2017

2171-2181

1 reference

3 August 2017

11

1 reference

Chronic myelogenous leukemia: biology and therapy

3 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

Chronic myeloid leukemia: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Correlates of return to work for breast cancer survivors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Punish the parent not the progeny.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Development of farnesyl transferase inhibitors: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

New targeted approaches in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22661

7 January 2021

Identifiers

DOI

10.1002/CNCR.22661

1 reference

3 August 2017

1 reference

PubMed ID

17431887